Difference between revisions of "Maprotiline-agomelatine"

From Psychiatrienet
Jump to: navigation, search
Line 9: Line 9:
 
| start =  
 
| start =  
 
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
 
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 14:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. }}
+
* '''Day 14:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.  
 +
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
 +
}}

Revision as of 11:27, 5 March 2010

Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from maprotiline to agomelatine.[1] [2]

Nietinrijdenbord.png Stop maprotiline
  • Before day 1: gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
  • Day 1: reduce dosage of maprotiline to 50 mg/day.
  • Day 7: reduce dosage of maprotiline to 25 mg/day.
  • Day 14: stop dosage of maprotiline.
Eenrichtingbord.png Start agomelatine
  • Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
  • Day 14: only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.

[3]


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.